The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab

Oncology and Hematology Associates of Southwest Virginia, US Oncology Research, McKesson Specialty Health, Blacksburg, USA
Amgen

Research output: Contribution to journal › Article › peer-review

Disciplines

@article{af72e981b22441a6bb0107b7cb9e4cb5,

title = "The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab",

author = "Jerome Goldschmidt and Vladimir Hanes",

year = "2021",

month = jun,

day = "1",

doi = "10.1007/S40487-020-00133-1",

language = "American English",

volume = "9",

journal = "Oncology and Therapy",

number = "1",

}

TY - JOUR

T1 - The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab

AU - Goldschmidt, Jerome

AU - Hanes, Vladimir

PY - 2021/6/1

Y1 - 2021/6/1

UR - https://link.springer.com/content/pdf/10.1007/s40487-020-00133-1.pdf

U2 - 10.1007/S40487-020-00133-1

DO - 10.1007/S40487-020-00133-1

M3 - Article

VL - 9

JO - Oncology and Therapy

JF - Oncology and Therapy

IS - 1

ER -